A Agilent Technologies Inc.

Agilent Opens Customer Experience Center Highlighting Genomics and Diagnostics Solutions

. (NYSE: A) today announced the opening of a new Customer Experience Center (CEC) in Lexington, MA, focused on solutions from Agilent genomics and diagnostics product portfolios. The facility will serve as a regional hub for Agilent representatives to showcase and demonstrate both product capabilities and complete workflow solutions to customers.

Hands-on training, education, assay development, and optimization are critical to a laboratory’s success. Scientists are looking for suppliers to support their discovery work and product and solution development efforts. The new Agilent CEC delivers an immersive experience for pathologists, clinicians, and researchers to increase their confidence in using Agilent products to meet the unique needs of their lab. The facility is strategically located where Agilent has a high concentration of genomics and pathology customers who can easily access the CEC.

The new CEC boasts an efficient layout to demonstrate workflows for next-generation sequencing (NGS) and pathology in clinical and research applications. It also provides a location for novel application development and collaborations. The suite of Agilent genomics and pathology instrumentation, paired with the expertise of Agilent’s technical staff, provides the necessary combination to support customers with needed comprehensive training while continuing to foster collaboration between Agilent and their customers.

“The Agilent genomics and diagnostics customer base continues to expand, and we are committed to supporting their success through hands-on and virtual training experiences,” said Sam Raha, president of Agilent’s Diagnostics and Genomics Group. “We are thrilled to open this innovative new Customer Experience Center in Lexington, designed as a modern laboratory to facilitate highly interactive education, training, and collaboration with our customers.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that advance the quality of life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent . Follow Agilent on , , and .

EN
05/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Agilent Technologies, Inc.: Key facts and statistics - fiscal 2025

A summary company profile, detailing Agilent Technologies, Inc.’s business operations and financial highlights.

Agilent Technologies, Inc. - October 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Agilent Technologies, Inc.: Update to credit analysis

Our credit view of this issuer reflects its low financial leverage, against its high proportion of revenue from costly equipment sales, which has exposure to cyclical demand fluctuations

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Agilent Technologies, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 11 December 2025 in which we reassessed the appropriateness of the ratings in th...

Agilent Technologies Inc: 1 director

A director at Agilent Technologies Inc sold 2,600 shares at 149.812USD and the significance rating of the trade was 62/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch